Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Core Points - Crinetics Pharmaceuticals has appointed Tobin "Toby" Schilke as the new Chief Financial Officer, effective February 28, 2025, bringing over 25 years of global pharmaceutical experience [1][2] - The company is in a transformational stage, preparing for its first commercial launch and advancing multiple promising candidates through development [2] - Mr. Schilke's previous experience includes serving as CFO at Revance Therapeutics, where he oversaw finance and operations, supporting two product launches and generating over $700 million in cumulative revenue [2] - The company plans to grant Mr. Schilke 52,000 restricted stock units and a stock option to purchase 80,000 shares, with vesting schedules tied to continued employment [3] - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases, with lead candidate paltusotine in clinical development for acromegaly and carcinoid syndrome [4] Company Overview - Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for endocrine diseases and related tumors [4] - The company's lead development candidate, paltusotine, is the first investigational oral selective somatostatin receptor type 2 nonpeptide agonist [4] - Other drug candidates in development include treatments for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with a focus on orally delivered small molecules [4]